natgillin/translations-raw huggingface dataset:
Simponi treatment is to be initiated and supervised by qualified physicians experienced in the diagnosis and treatment of rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, or ulcerative colitis.
Zdravljenje z zdravilom Simponi mora uvesti in nadzorovati usposobljen zdravnik, ki ima izkušnje s področja diagnostike in zdravljenja revmatoidnega artritisa, poliartikularnega juvenilnega idiopatskega artritisa, psoriatičnega artritisa, ankilozirajočega spondilitisa, neradiografskega aksialnega spondiloartritisa ali ulceroznega kolitisa.
Simponi treatment is to be initiated and supervised by qualified physicians experienced in the diagnosis and treatment of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, or ulcerative colitis.
Zdravljenje z zdravilom Simponi mora uvesti in nadzorovati usposobljen zdravnik, ki ima izkušnje s področja diagnostike in zdravljenja revmatoidnega artritisa, psoriatičnega artritisa, ankilozirajočega spondilitisa, neradiografskega aksialnega spondiloartritisa ali ulceroznega kolitisa.
Simponi treatment resulted in significant improvement in physical function as assessed by HAQ DI, as well as significant improvements in health-related quality of life as measured by the physical and mental component summary scores of the SF-36.
Zdravljenje z zdravilom Simponi je vodilo do bistvenega izboljšanja telesne funkcije, ki so jo ocenili z vprašalnikom HAQ DI, pa tudi do bistvenega izboljšanja z zdravjem povezane kakovosti življenja, ki so jo merili z zbirnimi rezultati za telesno in duševno komponento vprašalnika SF-36.
Simponi works by blocking the action of a protein called ‘tumour necrosis factor alpha’ (TNF-α).
Zdravilo Simponi deluje tako, da zavira delovanje beljakovine, imenovane tumorje nekrotizirajoči faktor alfa (TNF-α).
Simponi, alone or in combination with MTX, is indicated for the treatment of active and progressive psoriatic arthritis in adult patients when the response to previous DMARD therapy has been inadequate.
Zdravilo Simponi, samo ali v kombinaciji z metotreksatom, je indicirano za zdravljenje aktivnega in napredujočega psoriatičnega artritisa pri odraslih, pri katerih je bil odziv na prejšnje zdravljenje z
Simponi, alone or in combination with MTX, is indicated for the treatment of active and progressive psoriatic arthritis in adult patients when the response to previous DMARD therapy has been inadequate.
Zdravilo Simponi, samo ali v kombinaciji z metotreksatom, je indicirano za zdravljenje aktivnega in napredujočega psoriatičnega artritisa pri odraslih, pri katerih je bil odziv na prejšnje zdravljenje z DMARD nezadosten.
Simponi, in combination with methotrexate (MTX), is indicated for: the treatment of moderate to severe, active rheumatoid arthritis in adults when the response to disease-modifying anti-rheumatic drug (DMARD) therapy including MTX has been inadequate. the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with MTX.
Zdravilo Simponi v kombinaciji z metotreksatom (MTX) je indicirano za: zdravljenje zmernega do hudega, aktivnega revmatoidnega artritisa pri odraslih, če je bil odziv na zdravljenje z antirevmatiki, ki vplivajo na potek bolezni (disease-modifying anti-rheumatic drug - DMARD), vključno z metotreksatom, nezadosten; zdravljenje hudega, aktivnega in napredujočega revmatoidnega artritisa pri odraslih, ki predhodno niso bili zdravljeni z metotreksatom.
Simponi, in combination with MTX, has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function.
Uporaba zdravila Simponi v kombinaciji z metotreksatom je pokazala zmanjšanje hitrosti napredovanja okvare sklepov, kar so merili z rentgenskim slikanjem, in izboljšanje delovanja sklepov.
Simulated exposure data show that the overall AUC approximately doubles when a second dose is administered at 10, 30 and 60 minutes following the first dose.
Simulirani podatki o izpostavljenosti kažejo, da se celokupni AUC približno podvoji, če damo drugi odmerek 10, 30 ali 60 minut po prvem.
Simulated pharmacokinetic parameters for the recommended posology in children aged 3 months to less than 18 years, based on a population pharmacokinetic study are provided in tabulated format below:
Simulirani farmakokinetični parametri za priporočeno dajanje otrokom starim od 3 mesece do manj kot 18 let na podlagi farmakokinetičnih študij populacije so navedeni spodaj v obliki preglednice:
Simulation of 2-3 missed daily doses resulted in a median serum IgG level decrease of ≤ 4% compared to consistent daily dosing.
Simulacija z izpuščenimi 2–3 dnevnimi odmerki je povzročila mediano zmanjšanje ravni IgG v serumu za ≤ 4 % v primerjavi z doslednim vsakodnevnim odmerjanjem.
Simulations by empirical Population Pharmacokinetic models suggest that comparable IgG exposure levels (AUC0-14days, Cmin 14days) may be obtained if Hizentra is administered subcutaneously every two weeks using double the weekly dose during maintenance therapy.
Simulacije z empiričnimi modeli populacijske farmakokinetike kažejo, da je mogoče primerljive ravni izpostavljenosti IgG (AUC0-14dni, Cmin 14dni) doseči, če se daje zdravilo Hizentra subkutano vsaka dva tedna z uporabo dvojnega tedenskega odmerka v času vzdrževalne terapije.
Simulations using clinically relevant fasted conditions suggested that the mild CYP3A4 inhibitors azithromycin and fluvoxamine may increase the AUC of ibrutinib by < 2-fold.
Simulacije v klinično pomembnem stanju na tešče kažejo, da šibka zaviralca CYP3A4 azitromicin in fluvoksamin lahko povečata AUC ibrutiniba za < 2-krat.
Simulations using fasted conditions suggested that moderate CYP3A4 inhibitors, diltiazem, erythromycin and voriconazole, may increase the AUC of ibrutinib 5-9 fold.
Simulacije v teščem stanju kažejo, da lahko zmerni zaviralci CYP3A4 (diltiazem, eritromicin in vorikonazol), 5-9-krat povečajo AUC ibrutiniba.
Simulect 10 mg must not be administered unless it is absolutely certain that the patient will receive the graft and concomitant immunosuppression.
Simulecta 10 mg ne smemo uporabiti, če ni popolnoma gotovo, da bo bolnik dobil presadek in spremljajočo imunosupresijo.
Simulect 10 mg powder and solvent for solution for injection or infusion
Simulect 10 mg prašek in vehikel za raztopino za injiciranje ali infundiranje baziliksimab
Simulect 20 mg powder and solvent for solution for injection or infusion
Simulect 20 mg prašek in vehikel za raztopino za injiciranje ali infundiranje baziliksimab
Simulect can be given to children and adolescents.
Simulect lahko dobijo otroci in mladostniki.
Simulect can be given to older patients, but the information available is limited.
Simulect lahko dobijo starejši bolniki, vendar je na voljo malo podatkov.
Simulect comes as a white powder in a colourless glass vial containing 10 mg of basiliximab.
Simulect je na voljo v obliki praška v prozorni stekleni viali, ki vsebuje 10 mg baziliksimaba.
Simulect comes as a white powder in a colourless glass vial containing 20 mg of basiliximab.
Simulect je na voljo v obliki praška v prozorni stekleni viali, ki vsebuje 20 mg baziliksimaba.
Simulect is also available in vials with 10 mg basiliximab.
Simulect je na voljo tudi v vialah po 10 mg baziliksimaba.
Simulect is also available in vials with 10 mg basiliximab.
Simulect je na voljo tudi v vialah z 10 mg baziliksimaba.
Simulect is also available in vials with 20 mg basiliximab.
Simulect je na voljo tudi v vialah po 20 mg baziliksimaba.
Simulect is also available in vials with 20 mg basiliximab.
Simulect je na voljo tudi v vialah z 20 mg baziliksimaba.
Simulect is given to stop your body from rejecting the new organ during the first 4 to 6 weeks after the transplant operation, when rejection is most likely.
Simulect boste dobili zato, da vašemu telesu prepreči zavrnitev novega organa v prvih 4 do 6 tednih po presaditveni operaciji, ko je zavrnitev najverjetnejša.
Simulect is indicated for the prophylaxis of acute organ rejection in de novo allogeneic renal transplantation in adult and paediatric patients (1-17 years) (see section 4.2).
Simulect je indiciran za profilakso akutne zavrnitve organa pri de novo alogeni presaditvi ledvice pri odraslih in pediatričnih bolnikih (1-17 let) (glejte poglavje 4.2).
Simulect is to be used concomitantly with ciclosporin for microemulsion- and corticosteroid-based immunosuppression.
Simulect naj se uporablja za imunosupresijo sočasno s ciklosporinom v mikroemulziji in kortikosteroidi.
Simulect may harm your baby.
Simulect lahko škoduje vašemu otroku.
Simulect must not be administered unless it is absolutely certain that the patient will receive the graft and concomitant immunosuppression.
Simulecta bolnik ne sme prejeti, če ni popolnoma gotovo, da bo dobil presadek in sočasno imunosupresijo.
Simulect must not be administered unless it is absolutely certain that the patient will receive the graft and concomitant immunosuppression.
Simulecta ne smemo uporabiti, če ni popolnoma gotovo, da bo bolnik dobil presadek in spremljajočo imunosupresijo.
Simulect should be administered under qualified medical supervision.
Simulect naj se uporablja pod strokovnim medicinskim nadzorom.
Simulect should be prescribed only by physicians who are experienced in the use of immunosuppressive therapy following organ transplantation.
Simulect naj predpisujejo le zdravniki, ki imajo izkušnje z uporabo imunosupresivnega zdravljenja po presaditvi organov.
Simulect works by stopping the immune cells that attack transplanted organs.
Simulect deluje tako, da imunskim celicam prepreči, da bi napadale presajene organe.
Simultaneous administration of Cyanokit and other products
Sočasna uporaba zdravila Cyanokit in drugih zdravil
Simultaneous administration of five implants during a one- year period was well tolerated.
Prenašanje sočasne uporabe petih implantatov v obdobju enega leta je bilo dobro.
Simultaneous administration of ulipristal acetate and a P-gp substrate has not been studied and an interaction cannot be excluded.
Sočasne uporabe ulipristalacetata in substrata P–gp niso raziskali, tako da interakcije ni mogoče izključiti.
Simultaneous administration with cimetidine may lead to increased plasma levels of clomipramine.
Istočasno dajanje cimetidina povzroči dvig plazemske koncentracije klomipramina.
Simultaneous one-sided 97.5% confidence intervals for the vaccine efficacy of each influenza vaccine relative to placebo based on the Sidak-corrected score confidence intervals for the two relative risks.
Sočasni enostranski 97,5-odstotni intervali zaupanja za učinkovitost cepljenja s cepivi proti gripi glede na placebo, ki temeljijo na Šidakovih intervalih zaupanja s korekcijo točk za obe vrednosti relativnega tveganja.
Simultaneous vaccination with live vaccines increases the risk of severe infections attributable to the immunosuppressive activity of Oncaspar and overall situation taking into account the underlying disease and the usually combined chemotherapy (see section 4.4).
Sočasno cepljenje z živimi cepivi poveča tveganje za hude okužbe, kar je posledica imunosupresivne aktivnosti zdravila Oncaspar in celotnega stanja, vključno z osnovno boleznijo in običajno kombinirano kemoterapijo (glejte poglavje 4.4).
Simultaneously press down (2a) and turn the child- resistant cap (2b) to the left to open the bottle.
Steklenico odprete tako, da za otroke varno zaporko hkrati pritisnete navzdol (2a) in zavrtite v levo stran (2b).
Simultaneously press down (2a) and turn the child-resistant cap (2b) to the left to open the bottle.
Steklenico odprete tako, da za otroke varno zaporko hkrati pritisnete navzdol (2a) in zavrtite v levo stran (2b).
simultaneously with, and/or at least
skupaj s hrano, in sicer sočasno z
Simultaneously, liraglutide lowers inappropriately high glucagon secretion, also in a glucose­dependent manner.
Hkrati liraglutid zmanjšuje neprimerno veliko izločanje glukagona, prav tako odvisno od koncentracije glukoze.
Simultaneously, plasma concentrations of itraconazole may be increased by darunavir co-administered with low dose ritonavir.
Ob sočasni uporabi z darunavirjem z majhnim odmerkom ritonavirja se lahko zvečajo tudi plazemske koncentracije itrakonazola.
Simultaneously, plasma concentrations of itraconazole or ketoconazole may be decreased by INTELENCE.
Hkrati pa lahko zdravilo INTELENCE zniža plazemske koncentracije itrakonazola ali ketokonazola.
Simva 40
(mmol/l)
Simva 40
imva 40
Simvastatin
potreben, pri tem pa
Simvastatin
UČINEK
simvastatin acid AUC 1.88 (1.63-2.17) ↑
AUC 2-OH-atorvastatina 2,29 (2,08-2,52) 
simvastatin acid Cmax 3.03 (2.49-3.69) ↑
Cmax 2-OH-atorvastatina 1,98 (1,70-2,31) 
simvastatin AUC 1.51 (1.32-1.73) ↑
premljajte varnost
simvastatin Cmin not studied
Cmin atorvastatina niso proučevali
Simvastatin Co-administration of multiple doses of 10 mg amlodipine with 80 mg simvastatin resulted in a 77% increase in exposure to simvastatin compared to simvastatin alone.
simvastatin Pri večkratnem sočasnem odmerjanju amlodipina 10 mg in simvastatina 80 mg je prišlo do 77 % večje izpostavljenosti simvastatinu kot pri odmerjanju samo simvastatina.
Simvastatin is a substrate of CYP 3A4.
Simvastatin je substrat CYP 3A4.
Simvastatin is an inactive lactone which is readily hydrolyzed in vivo to the corresponding beta-hydroxyacid, a potent inhibitor of HMG-CoA reductase.
Simvastatin je neaktiven lakton, ki se in vivo hitro hidrolizira v ustrezno betahidroksi kislino, ki močno zavira reduktazo HMG-CoA.
Simvastatin Lovastatin (saquinavir/ritonavir)
imvastatin lovastatin (sakvinavir/ritonavir)
simvastatin should not exceed a daily dose
simvastatina med sočasno uporabo z
Simvastatin – Co-administration of ticagrelor with simvastatin increased simvastatin Cmax by 81% and AUC by 56% and increased simvastatin acid Cmax by 64% and AUC by 52% with some individual increases equal to 2 to 3 fold.
Simvastatin – Sočasna uporaba tikagrelorja in simvastatina je povečala Cmax simvastatina za 81 % in njegovo AUC za 56 %; Cmax simvastatinske kisline je povečala za 64 % in njeno AUC za 52 %, pri nekaterih posameznikih pa so bila povečanja 2- do 3-kratna.
Simvastatin – Co-administration of ticagrelor with simvastatin increased simvastatin Cmax by 81% and AUC by 56% and increased simvastatin acid Cmax by 64% and AUC by 52% with some individual increases equal to 2 to 3-fold.
Simvastatin – Sočasna uporaba ticagrelorja in simvastatina je povečala Cmax simvastatina za 81 % in njegovo AUC za 56 %; Cmax simvastatinske kisline je povečala za 64 % in njeno AUC za 52 %, pri nekaterih posameznikih pa so bila povečanja 2- do 3-kratna.
simvastatin, lovastatin or atorvastatin (used to lower cholesterol).
simvastatin, lovastatin ali atorvastatin (ki se uporabljajo za zniževanje holesterola).
Simvastatin/efavirenz (40 mg once daily/600 mg once daily)
(40 mg enkrat na dan/600 mg
Simvastatin/Efavirenz (40 mg once daily/600 mg once daily)
imvastatin/efavirenz (40 mg enkrat na dan/600 mg enkrat na dan)
Simvastatin: co-administration of bosentan 125 mg twice daily for 5 days decreased the plasma concentrations of simvastatin (a CYP3A4 substrate) and its active -hydroxy acid metabolite by 34% and 46%, respectively.
Simvastatin: pri sočasni uporabi bosentana v odmerku 125 mg dvakrat na dan 5 dni se je plazemska koncentracija simvastatina (substrat CYP3A4) znižala za 34 %, plazemska koncentracija njegovega aktivnega presnovka beta-hidroksi kisline pa za 46 %.
Since 2007 resistance associated H275Y mutation in seasonal H1N1 strains has become widespread.
Od leta 2007 se je odpornost, povezana z mutacijo H275Y, v sezonskih sevih H1N1 široko razširila.
Since 6–mercaptopurine pharmacokinetics has not been formally studied in hepatic impairment, no specific dose recommendations can be given.
Ker farmakokinetika 6-merkaptopurina pri okvarjenem delovanju jeter ni bila uradno raziskana, ni mogoče priporočiti določenega odmerka.
Since 6–mercaptopurine pharmacokinetics has not been formally studied in renal impairment, no specific dose recommendations can be given.
Ker farmakokinetika 6-merkaptopurina pri okvarjenem delovanju ledvic ni bila uradno raziskana, ni mogoče priporočiti določenega odmerka.
Since a benign enlargement of the prostate and prostate cancer may present the same symptoms, your doctor will check you for prostate cancer before starting treatment with Silodyx.
Ker imata nenevarno povečanje prostate in rak prostate lahko enake simptome, vas bo zdravnik pred pričetkom zdravljenja z zdravilom Silodyx poslal na kontrolni pregled za raka prostate.
Since a benign enlargement of the prostate and prostate cancer may present the same symptoms, your doctor will check you for prostate cancer before starting treatment with Urorec.
Ker imata nenevarno povečanje prostate in rak prostate lahko enake simptome, vas bo zdravnik pred pričetkom zdravljenja z zdravilom Urorec poslal na kontrolni pregled za raka prostate.
Since Acetylsalicylic acid, Nonsteroidal Anti-Inflammatory medicinal products (NSAIDs) and bisphosphonates are associated with gastrointestinal irritation, caution should be taken during concomitant administration (see section 4.4).
Ker acetilsalicilno kislino, nesteroidna protivnetna zdravila (NSAID) in difosfonate povezujejo z gastrointestinalnim draženjem, je pri sočasnem jemanju potrebna previdnost (glejte poglavje 4.4).
Since Acetylsalicylic acid, Nonsteroidal Anti-Inflammatory medicinal products (NSAIDs) and bisphosphonates are associated with gastrointestinal irritation, caution should be taken during concomitant administration (see section 4.4).
Ker acetilsalicilno kislino, nesteroidna protivnetna zdravila (NSAID) in difosfonate povezujejo z gastrointestinalnim draženjem, je pri sočasnem jemanju teh zdravil potrebna previdnost (glejte poglavje 4.4).
Since Acetylsalicylic acid, Nonsteroidal Anti-Inflammatory medicinal products (NSAIDs) and bisphosphonates are associated with gastrointestinal irritation, caution should be taken during concomitant administration (see section 4.4).
Ker so acetilsalicilna kislina, nesteroidna protivnetna zdravila in difosfonati povezani z draženjem prebavil, je med sočasnim dajanjem potrebna previdnost (glejte poglavje 4.4).
Since Acetylsalicylic acid, Nonsteroidal Anti-Inflammatory medicinal products (NSAIDS) and bisphosphonates are associated with gastrointestinal irritation, caution should be taken during concomitant administration.
Ker acetilsalicilno kislino, nesteroidna protivnetna zdravila (NSAID) in difosfonate povezujejo z gastrointestinalnim draženjem, je pri sočasnem jemanju teh zdravil potrebna previdnost.
Since an evaluation of the post-marketing safety database for Caelyx in patients has not suggested a significant nephrotoxicity liability of Caelyx, these findings in monkeys may not have relevance to patient risk assessment.
Ker ovrednotenje podatkovne baze o varnosti zdravila Caelyx za bolnike v postmarketinškem obdobju ni pokazalo bistvene nefrotoksične obremenitve zaradi jemanja zdravila Caelyx, omenjeni izsledki pri opicah morda niso pomembni za oceno tveganja pri bolnikih.
Since an indirect interaction between components of the oral contraception and pegaspargase cannot be ruled out , oral contraceptives are not considered sufficiently safe in such clinical situation.
Ker posredne interakcije med komponentami peroralne kontracepcije in pegaspargaze ni mogoče izključiti, peroralnih kontraceptivov ne štejemo za dovolj varne v takšni klinični situaciji.
Since an indirect interaction between components of the oral contraception and pegaspargase cannot be ruled out, oral contraceptives are not considered sufficiently safe in such clinical situation (see sections 4.5 and 4.6).
Ker posredne interakcije med komponentami peroralne kontracepcije in pegaspargaze ni mogoče izključiti, peroralnih kontraceptivov ne štejemo za dovolj varne v takšni klinični situaciji (glejte poglavji 4.5 in 4.6).
Since androgen deprivation treatment may prolong the QT interval, caution is advised when administering ZYTIGA with medicinal products known to prolong the QT interval or medicinal products able to induce Torsade de pointes such as class IA (e.g. quinidine, disopyramide) or class III (e.g. amiodarone, sotalol, dofetilide, ibutilide) antiarrhythmic medicinal products, methadone, moxifloxacin, antipsychotics, etc.
Zdravljenje z deprivacijo androgenov lahko podaljša QT interval, zato je pri uporabi zdravila ZYTIGA, skupaj z zdravili, ki podaljšajo QT interval ali zdravili, ki lahko sprožijo torsade de pointes razreda IA (na primer kinidin, dizopramid) ali razreda III (na primer amiodaron, sotalol, dofetilid, ibutilid), antiaritmiki, metadonom, moksifloksacinom, antipsihotiki, itd. potrebna previdnost.
Since androgen deprivation treatment may prolong the QTc interval, the concomitant use of degarelix with medicinal products known to prolong the QTc interval or medicinal products able to induce torsades de pointes such as class IA (e.g. quinidine, disopyramide) or class III (e.g. amiodarone, sotalol, dofetilide, ibutilide) antiarrhythmic medicinal products, methadone, , moxifloxacin, antipsychotics, etc. should be carefully evaluated (see section 4.4).
Ker zdravljenje z deprivacijo androgenov lahko podaljša interval QTc, moramo skrbno ovrednotiti sočasno uporabo degareliksa z zdravili, za katere je znano, da podaljšujejo interval QTc, ali zdravili, ki lahko sprožijo torsades de pointes, n.pr. antiaritmiki skupine IA (kinidin, dizopiramid) ali skupine III (n.pr. amiodaron, sotalol, dofetilid, ibutilid), metadon, moksifloksacin, antipsihotiki itn. (glejte poglavje 4.4).
Since androgen deprivation treatment may prolong the QTc interval, the concomitant use of degarelix with medicinal products known to prolong the QTc interval or medicinal products able to induce torsades de pointes such as class IA (e.g. quinidine, disopyramide) or class III (e.g. amiodarone, sotalol, dofetilide, ibutilide) antiarrhythmic medicinal products, methadone, moxifloxacin, antipsychotics, etc. should be carefully evaluated (see section 4.4).
Ker zdravljenje z deprivacijo androgenov lahko podaljša interval QTc, moramo skrbno ovrednotiti sočasno uporabo degareliksa z zdravili, za katere je znano, da podaljšujejo interval QTc, ali zdravili, ki lahko sprožijo torsades de pointes, n.pr. antiaritmiki skupine IA (kinidin, dizopiramid) ali skupine III (n.pr. amiodaron, sotalol, dofetilid, ibutilid), metadon, moksifloksacin, antipsihotiki itn. (glejte poglavje 4.4).
Since Aptivus capsules and oral solution are not bioequivalent, results obtained with the oral solution cannot be extrapolated to the capsules (see also section 5.2).
Ker kapsule in peroralna raztopina Aptivus nimata enake biološke uporabnosti, izsledkov o peroralni raztopini ne moremo prenašati na kapsule (glejte tudi poglavje 5.2).
Since atazanavir is extensively metabolised by the liver and is highly protein bound, dialysis is unlikely to be beneficial in significant removal of this medicinal product.
Atazanavir se izdatno presnavlja v jetrih in se v veliki meri veže na beljakovine v plazmi, zato ni verjetno, da bi dializa kaj dosti koristila pri njegovi odstranitvi.
Since Atriance has been approved under exceptional circumstances, the company that markets Atriance will provide further information on the safety of Atriance in children and young adults from a study of Atriance taken in combination with other cancer medicines.
Ker je zdravilo Atriance pridobilo dovoljenje za promet „v izjemnih okoliščinah“, bo družba, ki ga trži, priskrbela dodatne informacije o njegovi varnosti pri otrocih in mladih iz študije, v kateri so zdravilo uporabljali v kombinaciji z drugimi zdravili za zdravljenje raka.
Since AUBAGIO tablets contain lactose, patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption, should not take this medicinal product.
Ker tablete zdravila AUBAGIO vsebujejo laktozo, bolniki z redkimi dednimi boleznimi galaktozne intolerance, laponsko obliko zmanjšane aktivnosti laktaze ali malabsorpcije glukoze-galaktoze ne smejo jemati tega zdravila.